News Headlines Article

Amgen, Allergan say their Avastin biosimilar showing positive results
Los Angeles Business Journal

Amgen Inc. and Allergan plc said their biosimilar candidate to treat lung cancer has shown positive results in a late-stage study that brings it one step towards coming to market as a competitor to Roche AG’s Avastin. Thousand Oaks-based Amgen(Nasdaq: AMGN) and Irvine-based Allergan(NYSE: AGN) said their drug candidate, ABP 215, has shown to be as effective as Avastin in shrinking tumors and improving survival rates among patients with advanced non-small cell lung cancer.